Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dendritic cell-based immunotherapy in thyroid malignancies.

Matthias Schott1, Werner A Scherbaum, Jochen Seissler

  • 1Department of Endocrinology, Heinrich-Heine-University Duesseldorf, Moorenstr.5, 40225, Germany. schottmt@uni-duesseldorf.de

Current Drug Targets. Immune, Endocrine and Metabolic Disorders
|September 24, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implantable vascularized endocrine constructs for clinically scalable insulin delivery.

Trends in biotechnology·2026
Same author

Outcome Of First-Line Chemotherapy For Anaplastic Thyroid Cancer - A Multicenter Registry Analysis.

The Journal of clinical endocrinology and metabolism·2026
Same author

Clinical Evaluation of a New Automated Bridge Assay for the Detection of Thyroid-Stimulating Hormone Receptor Autoantibodies.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2026
Same author

Papillary Thyroid Carcinoma and Hashimoto's Thyroiditis: New Insights into the Immunological Link.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2025
Same author

Factors Associated with Hypoparathyroidism and Vocal Cord Paralysis Following Thyroid Surgery: A Multicenter Cross-Sectional Analysis of 3,365 Cases.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2025
Same author

Type 1 Diabetes and Other Autoimmune Diseases-Epidemiology, Pathophysiology and Screening.

Endocrinology, diabetes & metabolism·2025

Dendritic cell (DC) vaccines show promise in cancer immunotherapy by activating immune cells to target tumor antigens. Clinical trials indicate DC vaccinations can lead to remission in some cancer patients, particularly endocrine malignancies.

Area of Science:

  • Immunology
  • Oncology
  • Vaccine Development

Background:

  • Dendritic cells (DCs) are potent antigen-presenting cells crucial for initiating adaptive immune responses.
  • DCs can activate T helper cells and cytotoxic T cells, making them valuable for anti-tumor immunotherapy.
  • Clinical trials have shown that tumor antigen-pulsed DC immunizations can overcome immune tolerance in cancer patients.

Purpose of the Study:

  • To review the interaction between dendritic cells (DCs), T cells, and natural killer cells in anti-tumor immunity.
  • To summarize recent findings on DC vaccination strategies for both endocrine and non-endocrine malignancies.
  • To evaluate the potential of DC vaccination as a novel anti-cancer therapeutic approach.

Main Methods:

  • Review of existing literature on DC-T cell and DC-NK cell interactions.

Related Experiment Videos

  • Analysis of clinical trial data from DC vaccination studies in various cancers.
  • Focus on DC vaccination efficacy in endocrine and radioresistant malignancies.

    • Main Results:

    • DC vaccination has demonstrated the ability to break immune tolerance against tumor-specific antigens.
    • Partial or complete remission has been observed in some patients following DC-based immunizations.
    • DC vaccination shows particular promise for treating chemotherapy and radioresistant endocrine malignancies.

    Conclusions:

    • Dendritic cell vaccination is a promising strategy for developing effective anti-cancer vaccines.
    • DC vaccination can elicit active immune responses against tumor antigens.
    • This approach may offer a new therapeutic avenue for difficult-to-treat endocrine cancers.